Stocks · News reference
Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
SERES THERAPEUTICS, INC.$300,000,000Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $(2.19) by 121.56 percent. This is a 120.7 percent increase over losses of $(2.27) per share
Filed: 2026-08-05 AccNo: 0001193125-26-333820 Size: 241 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits